Copyright
©The Author(s) 2022.
World J Gastroenterol. Mar 21, 2022; 28(11): 1123-1138
Published online Mar 21, 2022. doi: 10.3748/wjg.v28.i11.1123
Published online Mar 21, 2022. doi: 10.3748/wjg.v28.i11.1123
Table 1 Current evidence about available prognostic factors for either metastatic spread or tumor progression/recurrence in rectal neuroendocrine neoplasms
| Prognostic factor | Cut-off | Risk of metastases | Evidence |
| Tumor size | 15 mm | 14% | Retrospective large study[27] |
| Grading | G2 | 50% | Retrospective study[30] |
| G3 | 33% | Retrospective study[30] | |
| Lymph node status | N2 (≥ 5 positive lymph nodes) | Not quantified | Retrospective study[35] |
| Depth of invasion | Invasion of the muscolaris propria | Not quantified | Retrospective study[37] |
- Citation: Gallo C, Rossi RE, Cavalcoli F, Barbaro F, Boškoski I, Invernizzi P, Massironi S. Rectal neuroendocrine tumors: Current advances in management, treatment, and surveillance. World J Gastroenterol 2022; 28(11): 1123-1138
- URL: https://www.wjgnet.com/1007-9327/full/v28/i11/1123.htm
- DOI: https://dx.doi.org/10.3748/wjg.v28.i11.1123